{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=CHRONIC+DISEASE&page=74", "query": { "condition": "CHRONIC DISEASE", "page": 74 }, "page_size": 10 }, "pagination": { "page": 74, "page_size": 10, "total_count": 11586, "total_pages": 1159, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=CHRONIC+DISEASE&page=75&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=CHRONIC+DISEASE&page=73&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-10T10:05:38.911Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01113515", "title": "Clinical Investigation of Galnobax® for the Treatment of Diabetic Foot Ulcers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Diabetic Foot Ulcer" ], "interventions": [ { "name": "Esmolol hydrochloride", "type": "DRUG" }, { "name": "Placebo gel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novalead Pharma Private Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "95 Years", "sex": "ALL", "summary": "18 Years to 95 Years" }, "enrollment_count": 44, "start_date": "2014-02-20", "completion_date": "2015-10-17", "has_results": true, "last_update_posted_date": "2024-05-20", "last_synced_at": "2026-11-10T10:05:38.911Z", "location_count": 1, "location_summary": "Providence, Rhode Island", "locations": [ { "city": "Providence", "state": "Rhode Island" } ], "official_url": "https://clinicaltrials.gov/study/NCT01113515" }, { "nct_id": "NCT05013606", "title": "Hydrogen Water Treatment for Chronic Fatigue Syndrome", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Chronic Fatigue Syndrome" ], "interventions": [ { "name": "Hydrogen water", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DIETARY_SUPPLEMENT" ], "sponsor": "Stony Brook University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "21 Years to 65 Years" }, "enrollment_count": 23, "start_date": "2019-04-01", "completion_date": "2021-06-01", "has_results": false, "last_update_posted_date": "2021-08-19", "last_synced_at": "2026-11-10T10:05:38.911Z", "location_count": 1, "location_summary": "Stony Brook, New York", "locations": [ { "city": "Stony Brook", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05013606" }, { "nct_id": "NCT01471652", "title": "Chronic Fatigue Syndrome: A Presumptive Mitochondrial Disorder", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Fatigue Syndrome" ], "interventions": [ { "name": "Nutraceutical supplements", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Columbia University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "25 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "25 Years to 55 Years" }, "enrollment_count": 0, "start_date": "2012-03", "completion_date": "2013-02", "has_results": false, "last_update_posted_date": "2015-04-13", "last_synced_at": "2026-11-10T10:05:38.911Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01471652" }, { "nct_id": "NCT00890747", "title": "Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Accelerated Phase Chronic Myelogenous Leukemia", "Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome", "Acute Undifferentiated Leukemia", "Adult Acute Lymphoblastic Leukemia in Remission", "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Del(5q)", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Adult Grade III Lymphomatoid Granulomatosis", "Adult Langerhans Cell Histiocytosis", "Adult Nasal Type Extranodal NK/T-cell Lymphoma", "Aggressive NK-cell Leukemia", "AIDS-related Diffuse Large Cell Lymphoma", "AIDS-related Diffuse Mixed Cell Lymphoma", "AIDS-related Diffuse Small Cleaved Cell Lymphoma", "AIDS-related Immunoblastic Large Cell Lymphoma", "AIDS-related Lymphoblastic Lymphoma", "AIDS-related Malignancies", "AIDS-related Small Noncleaved Cell Lymphoma", "Anaplastic Large Cell Lymphoma", "Angioimmunoblastic T-cell Lymphoma", "Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative", "Chronic Eosinophilic Leukemia", "Chronic Myelomonocytic Leukemia", "Chronic Neutrophilic Leukemia", "Chronic Phase Chronic Myelogenous Leukemia", "Clear Cell Renal Cell Carcinoma", "Cutaneous B-cell Non-Hodgkin Lymphoma", "de Novo Myelodysplastic Syndromes", "Essential Thrombocythemia", "Extramedullary Plasmacytoma", "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", "Hepatosplenic T-cell Lymphoma", "HIV Infection", "HIV-associated Hodgkin Lymphoma", "Intraocular Lymphoma", "Isolated Plasmacytoma of Bone", "Light Chain Deposition Disease", "Mast Cell Leukemia", "Myelodysplastic Syndrome With Isolated Del(5q)", "Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable", "Myeloid/NK-cell Acute Leukemia", "Nodal Marginal Zone B-cell Lymphoma", "Noncutaneous Extranodal Lymphoma", "Osteolytic Lesions of Multiple Myeloma", "Peripheral T-cell Lymphoma", "Plasma Cell Neoplasm", "Polycythemia Vera", "Post-transplant Lymphoproliferative Disorder", "Previously Treated Myelodysplastic Syndromes", "Primary Myelofibrosis", "Primary Systemic Amyloidosis", "Progressive Hairy Cell Leukemia, Initial Treatment", "Prolymphocytic Leukemia", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Myeloid Leukemia", "Recurrent Adult Burkitt Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Diffuse Mixed Cell Lymphoma", "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma", "Recurrent Adult Grade III Lymphomatoid Granulomatosis", "Recurrent Adult Hodgkin Lymphoma", "Recurrent Adult Immunoblastic Large Cell Lymphoma", "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent Adult T-cell Leukemia/Lymphoma", "Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Mycosis Fungoides/Sezary Syndrome", "Recurrent Renal Cell Cancer", "Recurrent Small Lymphocytic Lymphoma", "Refractory Chronic Lymphocytic Leukemia", "Refractory Hairy Cell Leukemia", "Refractory Multiple Myeloma", "Relapsing Chronic Myelogenous Leukemia", "Stage IV Renal Cell Cancer", "T-cell Large Granular Lymphocyte Leukemia", "Testicular Lymphoma", "Unspecified Adult Solid Tumor, Protocol Specific", "Waldenström Macroglobulinemia" ], "interventions": [ { "name": "sunitinib malate", "type": "DRUG" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2009-08", "completion_date": null, "has_results": false, "last_update_posted_date": "2014-03-17", "last_synced_at": "2026-11-10T10:05:38.911Z", "location_count": 11, "location_summary": "Los Angeles, California • Washington D.C., District of Columbia • Chicago, Illinois + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Rockville", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00890747" }, { "nct_id": "NCT00077155", "title": "Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "AIDS-related Peripheral/Systemic Lymphoma", "AIDS-related Primary CNS Lymphoma", "Anaplastic Large Cell Lymphoma", "Angioimmunoblastic T-cell Lymphoma", "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", "Intraocular Lymphoma", "Nodal Marginal Zone B-cell Lymphoma", "Recurrent Adult Burkitt Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Diffuse Mixed Cell Lymphoma", "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma", "Recurrent Adult Hodgkin Lymphoma", "Recurrent Adult Immunoblastic Large Cell Lymphoma", "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent Adult T-cell Leukemia/Lymphoma", "Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Mycosis Fungoides/Sezary Syndrome", "Recurrent Small Lymphocytic Lymphoma", "Splenic Marginal Zone Lymphoma", "Stage III Adult Burkitt Lymphoma", "Stage III Adult Diffuse Large Cell Lymphoma", "Stage III Adult Diffuse Mixed Cell Lymphoma", "Stage III Adult Diffuse Small Cleaved Cell Lymphoma", "Stage III Adult Hodgkin Lymphoma", "Stage III Adult Immunoblastic Large Cell Lymphoma", "Stage III Adult Lymphoblastic Lymphoma", "Stage III Cutaneous T-cell Non-Hodgkin Lymphoma", "Stage III Grade 1 Follicular Lymphoma", "Stage III Grade 2 Follicular Lymphoma", "Stage III Grade 3 Follicular Lymphoma", "Stage III Mantle Cell Lymphoma", "Stage III Marginal Zone Lymphoma", "Stage III Mycosis Fungoides/Sezary Syndrome", "Stage III Small Lymphocytic Lymphoma", "Stage IV Adult Burkitt Lymphoma", "Stage IV Adult Diffuse Large Cell Lymphoma", "Stage IV Adult Diffuse Mixed Cell Lymphoma", "Stage IV Adult Diffuse Small Cleaved Cell Lymphoma", "Stage IV Adult Hodgkin Lymphoma", "Stage IV Adult Immunoblastic Large Cell Lymphoma", "Stage IV Adult Lymphoblastic Lymphoma", "Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma", "Stage IV Grade 1 Follicular Lymphoma", "Stage IV Grade 2 Follicular Lymphoma", "Stage IV Grade 3 Follicular Lymphoma", "Stage IV Mantle Cell Lymphoma", "Stage IV Marginal Zone Lymphoma", "Stage IV Mycosis Fungoides/Sezary Syndrome", "Stage IV Small Lymphocytic Lymphoma", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "cilengitide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "2003-12", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-01-24", "last_synced_at": "2026-11-10T10:05:38.911Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00077155" }, { "nct_id": "NCT00062699", "title": "Evaluate the Survival Benefits of Zemplar Versus Calcijex in Subjects w/ Stage V Chronic Kidney Disease on Hemodialysis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "End-Stage Kidney Disease" ], "interventions": [ { "name": "Zemplar (paricalcitol injection)", "type": "DRUG" }, { "name": "Calcijex", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Abbott", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "20 Years", "maximum_age": null, "sex": "ALL", "summary": "20 Years and older" }, "enrollment_count": 2200, "start_date": "2003-04", "completion_date": null, "has_results": false, "last_update_posted_date": "2006-08-02", "last_synced_at": "2026-11-10T10:05:38.911Z", "location_count": 60, "location_summary": "Tuscaloosa, Alabama • Inglewood, California • Los Angeles, California + 40 more", "locations": [ { "city": "Tuscaloosa", "state": "Alabama" }, { "city": "Inglewood", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Riverside", "state": "California" }, { "city": "San Pablo", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00062699" }, { "nct_id": "NCT06022887", "title": "Time-Restricted Eating and Mindfulness-Based Stress Reduction to Reduce the Risk of Early-Onset Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Obesity", "Colorectal Cancer", "Microbial Colonization", "Time Restricted Feeding", "Stress, Psychological" ], "interventions": [ { "name": "TRE", "type": "BEHAVIORAL" }, { "name": "MBSR", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Lisa Tussing-Humphreys", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "39 Years", "sex": "ALL", "summary": "18 Years to 39 Years" }, "enrollment_count": 43, "start_date": "2023-10-18", "completion_date": "2024-07-24", "has_results": false, "last_update_posted_date": "2024-08-21", "last_synced_at": "2026-11-10T10:05:38.911Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT06022887" }, { "nct_id": "NCT07321652", "title": "Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Lymphocytic Leukemia", "Small Lymphocytic Leukemia" ], "interventions": [ { "name": "Zanubrutinib", "type": "DRUG" }, { "name": "Sonrotoclax", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Survey Administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "PROCEDURE", "OTHER" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "65 Years", "maximum_age": null, "sex": "ALL", "summary": "65 Years and older" }, "enrollment_count": 466, "start_date": "2026-04-30", "completion_date": "2038-09-30", "has_results": false, "last_update_posted_date": "2026-11-03", "last_synced_at": "2026-11-10T10:05:38.911Z", "location_count": 261, "location_summary": "Birmingham, Alabama • Anaheim, California • Baldwin Park, California + 213 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anaheim", "state": "California" }, { "city": "Baldwin Park", "state": "California" }, { "city": "Bellflower", "state": "California" }, { "city": "Dublin", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07321652" }, { "nct_id": "NCT03088878", "title": "A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "B-cell Chronic Lymphocytic Leukemia", "Small Lymphocytic Lymphoma", "Mantle Cell Lymphoma", "Marginal Zone Lymphoma" ], "interventions": [ { "name": "Cirmtuzumab (2-16 kg/mg) plus Ibrutinib", "type": "DRUG" }, { "name": "Cirmtuzumab (300mg) plus Ibrutinib", "type": "DRUG" }, { "name": "Cirmtuzumab (600 mg) plus ibrutinib", "type": "DRUG" }, { "name": "Cirmtuzumab (RDR) plus ibrutinib", "type": "DRUG" }, { "name": "Cirmtuzumab plus ibrutinib", "type": "DRUG" }, { "name": "Ibrutinib alone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Oncternal Therapeutics, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 95, "start_date": "2018-01-03", "completion_date": "2024-09-25", "has_results": true, "last_update_posted_date": "2025-02-12", "last_synced_at": "2026-11-10T10:05:38.911Z", "location_count": 12, "location_summary": "Duarte, California • La Jolla, California • Sacramento, California + 8 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03088878" }, { "nct_id": "NCT01328626", "title": "A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Lymphocytic Leukemia", "Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "ABT-199", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 222, "start_date": "2011-05-23", "completion_date": "2020-05-08", "has_results": false, "last_update_posted_date": "2022-02-23", "last_synced_at": "2026-11-10T10:05:38.911Z", "location_count": 8, "location_summary": "Tucson, Arizona • La Jolla, California • Boston, Massachusetts + 4 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01328626" } ] }